RSV F antigen vaccine (Clover Biopharmaceuticals)

— Head-to-head clinical results indicate a potential best-in-class combined efficacy & safety profile of non-adjuvanted bivalent RSV vaccine candidate (SCB-1019) — — RSV neutralizing antibodies for Clover’s non-adjuvanted SCB-1019 matched GSK’s AS01 E -adjuvanted AREXVY in older adults, while demonstrating significantly better tolerability compared to AREXVY — — Clover plans to initiate clinical trials in 2025 evaluating SCB-1019 in an RSV re-vaccination setting and as part of a respiratory combination vaccine — SHANGHAI, China I October 28, 2024 I Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced positive additional immunogenicity and safety data in older adult & elderly subjects from its Phase Ⅰ trial evaluating SCB-1019 – the company’s non-adjuvanted bivalent RSV prefusion-stabilized F (PreF)-Trimer subunit vaccine candidate based on Clover’s Trimer-Tag vaccine technology platform – compared head-to-head with GSK’s AS01 E -adjuvanted RSV vaccine (AREXVY). “We are pleased to announce positive head-to-head clinical data for our non-adjuvanted SCB-1019 RSV vaccine candidate compared to AS01 E -adjuvanted AREXVY, indicating our potential best-in-class combined efficacy & safety profile,” said Joshua Liang, Chief Executive Officer & Board Director of Clover. “While currently approved protein-based RSV vaccines are safe & effective when given as an initial dose, the ability to re-vaccinate effectively when protection against RSV disease wanes and the prevention of respiratory disease caused by other viruses related to RSV both remain unaddressed & high unmet needs globally. We look forward to evaluating SCB-1019 in an RSV re-vaccination setting and as part of a respiratory combination vaccine in clinical trials in 2025.” In the ongoing Phase Ⅰ trial, 70 older adult & elderly subjects were enrolled and received either Clover’s SCB-1019, GSK’s AREXVY or saline placebo. Preliminary results for immunogenicity and safety for SCB-1019 are summarized below: Immunogenicity Results Safety & Reactogenicity Results Based on these positive Phase Ⅰ trial results, Clover plans to initiate clinical trials in 2025 evaluating SCB-1019 (non-adjuvanted bivalent RSV-A/B vaccine candidate) utilized in an RSV re-vaccination setting and as part of a respiratory combination vaccine. About Clover Clover Biopharmaceuticals is a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world. With integrated research and development, manufacturing and commercial capabilities as well as strong partnerships with organizations globally, Clover has a diverse pipeline of candidates that have the potential to meaningfully reduce the burden of vaccine-preventable diseases—and to make more diseases preventable. SOURCE: Clover Biopharma

-- Head-to-head clinical results indicate a potential best-in-class combined efficacy & safety profile of non-adjuvanted bivalent RSV vaccine candidate (SCB-1019) -- -- RSV neutralizing antibodies for Clover's non-adjuvanted SCB-1019 matched GSK's AS01E-adjuvanted AREXVY in older adults, while demonstrating significantly better tolerability compared to AREXVY -- -- Clover plans to initiate clinical trials in 2025 evaluating SCB-1019 in an RSV re-vaccination setting and as part of a respiratory combination vaccine -- SHANGHAI, Oct. 28, 2024 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced positive additional immunogenicity and safety data in older adult & elderly subjects from its Phase Ⅰ trial evaluating SCB-1019 – the company's non-adjuvanted bivalent RSV prefusion-stabilized F (PreF)-Trimer subunit vaccine candidate based on Clover's Trimer-Tag vaccine technology platform – compared head-to-head with GSK's AS01E-adjuvanted RSV vaccine (AREXVY). "We are pleased to announce positive head-to-head clinical data for our non-adjuvanted SCB-1019 RSV vaccine candidate compared to AS01E-adjuvanted AREXVY, indicating our potential best-in-class combined efficacy & safety profile," said Joshua Liang, Chief Executive Officer & Board Director of Clover. "While currently approved protein-based RSV vaccines are safe & effective when given as an initial dose, the ability to re-vaccinate effectively when protection against RSV disease wanes and the prevention of respiratory disease caused by other viruses related to RSV both remain unaddressed & high unmet needs globally. We look forward to evaluating SCB-1019 in an RSV re-vaccination setting and as part of a respiratory combination vaccine in clinical trials in 2025." In the ongoing Phase Ⅰ trial, 70 older adult & elderly subjects were enrolled and received either Clover's SCB-1019, GSK's AREXVY or saline placebo. Preliminary results for immunogenicity and safety for SCB-1019 are summarized below: Immunogenicity Results RSV Neutralizing Antibodies (nAbs): Non-adjuvanted SCB-1019 induced geometric mean titers (GMTs) in RSV-A and RSV-B nAbs that were comparable to AS01E-adjuvanted AREXVY at Day 28, with no statistically significant differences observed. RSV-A nAbs: SCB-1019 induced GMTs in RSV-A nAbs of approximately 30,500 IU/mL, compared to approximately 26,700 IU/mL for AREXVY and approximately 3,300 IU/mL for placebo at Day 28. RSV-B nAbs: SCB-1019 induced GMTs in RSV-B nAbs of approximately 32,000 IU/mL, compared to approximately 37,700 IU/mL for AREXVY and approximately 2,900 IU/mL for placebo at Day 28. RSV-B Specific Antibodies: SCB-1019 (bivalent RSV-A/B) included an approximately 1.5-fold higher trend in antibodies (Geometric Mean Ratio [GMR]) against a potent RSV-B specific neutralization epitope in Site V compared to AREXVY (monovalent RSV-A), based on an exploratory competitive-ELISA assay, indicating the potential for greater and more sustained immunological breadth upon re-vaccination if confirmed in subsequent studies. Safety & Reactogenicity Results Significantly lower rates of local adverse events (AEs) were observed for non-adjuvanted SCB-1019 (16.7%) compared to AS01E-adjuvanted AREXVY (76.7%). SCB-1019 was generally well-tolerated. Local and systemic AEs were generally mild for SCB-1019 and were comparable to saline placebo. No vaccine related serious adverse events (SAEs), adverse events of special interest (AESIs), or AEs leading to discontinuation were observed. Based on these positive Phase Ⅰ trial results, Clover plans to initiate clinical trials in 2025 evaluating SCB-1019 (non-adjuvanted bivalent RSV-A/B vaccine candidate) utilized in an RSV re-vaccination setting and as part of a respiratory combination vaccine. About Clover Clover Biopharmaceuticals is a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world. With integrated research and development, manufacturing and commercial capabilities as well as strong partnerships with organizations globally, Clover has a diverse pipeline of candidates that have the potential to meaningfully reduce the burden of vaccine-preventable diseases—and to make more diseases preventable.  Clover Forward-looking Statements This press release contains certain forward-looking statements and information relating to us and our subsidiaries that are based on the beliefs of our management as well as assumptions made by and information currently available to our management. When used, the words "aim," "anticipate," "believe," "could," "estimate," "expect," "going forward," "intend," "may," "might," "ought to," "plan," "potential," "predict," "project," "seek," "should," "will," "would" and the negative of these words and other similar expressions, as they relate to us or our management, are intended to identify forward-looking statements. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. We give no assurance that these expectations and assumptions will prove to have been correct. Because forward-looking statements relate to the future, they are participant to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. We caution you therefore against placing undue reliance on any of these forward-looking statements. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time. Clover Biopharmaceuticals: Corporate Communication: Lola Cao [email protected] Investor Relations: Michael Tu [email protected] SOURCE Clover Biopharma WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED